Scarica l'app Stockscreener
14.53
3.20%
-0.48
Dopo l'orario di chiusura:
14.32
-0.21
-1.45%
Precedente Chiudi:
$15.01
Aprire:
$15.24
Volume 24 ore:
437.89K
Relative Volume:
3.07
Capitalizzazione di mercato:
$102.02M
Reddito:
$5.75M
Utile/perdita netta:
$-38.96M
Rapporto P/E:
-1.1652
EPS:
-12.47
Flusso di cassa netto:
$-32.63M
1 W Prestazione:
+37.20%
1M Prestazione:
+95.03%
6M Prestazione:
+109.97%
1 anno Prestazione:
+141.36%
Intervallo 1D:
$13.57
$15.80
Intervallo di 1 settimana:
$10.39
$15.80
Portata 52W:
$2.92
$15.80
Kala Bio Inc Stock (KALA) Company Profile
Nome
Kala Bio Inc
Settore
Industria
Telefono
781-996-5252
Indirizzo
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Confronta KALA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
14.53 | 85.59M | 5.75M | -38.96M | -32.63M | -12.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-11 | Iniziato | Ladenburg Thalmann | Buy |
| 2022-03-30 | Downgrade | JP Morgan | Neutral → Underweight |
| 2021-08-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-09-14 | Downgrade | Jefferies | Buy → Hold |
| 2020-07-23 | Iniziato | Northland Capital | Outperform |
| 2020-06-01 | Ripresa | Oppenheimer | Outperform |
| 2020-05-27 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-09 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-12-17 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-03-14 | Iniziato | Jefferies | Buy |
Mostra tutto
Kala Bio Inc Borsa (KALA) Ultime notizie
KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewswire
How to read the order book for KALA BIO Inc.Weekly Trade Report & Weekly Breakout Opportunity Watchlist - Newser
Using data tools to time your KALA BIO Inc. exitWeekly Trend Recap & Short-Term Swing Trade Alerts - Newser
Rare Eye Disease Biotech KALA BIO to Present Latest Developments at H.C. Wainwright Conference - Stock Titan
Momentum divergence signals in KALA BIO Inc. chartJuly 2025 Action & Risk Managed Trade Strategies - Newser
Smart tools for monitoring KALA BIO Inc.’s price action2025 Pullback Review & Verified Momentum Watchlists - Newser
Visual trend scoring systems applied to KALA BIO Inc.Weekly Trade Recap & Community Verified Trade Signals - Newser
Is KALA BIO Inc. a candidate for recovery playMarket Growth Summary & Free Expert Approved Momentum Trade Ideas - Newser
Can KALA BIO Inc. weather a recession2025 Breakouts & Breakdowns & Community Consensus Picks - khodrobank.com
What data driven models say about KALA BIO Inc.’s futureTrade Risk Report & Low Risk High Reward Ideas - Newser
KALA BIO Inc.’s volatility index tracking explainedJuly 2025 PostEarnings & Advanced Swing Trade Entry Plans - Newser
What candlestick patterns are forming on KALA BIO Inc.Weekly Loss Report & High Conviction Trade Alerts - Newser
What’s the analyst consensus on KALA BIO Inc.2025 Price Action Summary & Long-Term Capital Growth Ideas - khodrobank.com
Can KALA BIO Inc. continue delivering strong returns2025 Valuation Update & Trade Opportunity Analysis - khodrobank.com
Will KALA BIO Inc. stock go up soonProduct Launch & Stepwise Trade Signal Implementation - Newser
Kala Bio appoints Todd Bazemore as CEO and director, updates compensation - Investing.com
KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director - The Manila Times
Rare Disease Expert Todd Bazemore Takes Helm at KALA BIO Ahead of Crucial Phase 2b Trial Results - Stock Titan
KALA BIO Soars 12.75% on CHASE Trial Anticipation - AInvest
Is KALA BIO Inc. showing insider buyingJuly 2025 Trends & Technical Pattern Recognition Alerts - khodrobank.com
Statistical indicators supporting KALA BIO Inc.’s strengthWeekly Trade Recap & High Return Trade Opportunity Guides - Newser
Can KALA BIO Inc. disrupt its industry2025 Trade Ideas & Free Fast Gain Swing Trade Alerts - khodrobank.com
Can KALA BIO Inc. rally from current levelsJuly 2025 Reactions & Momentum Based Trading Ideas - Newser
What MACD signals say about KALA BIO Inc.Risk Management & Fast Moving Market Watchlists - Newser
Tools to monitor KALA BIO Inc. recovery probability2025 Fundamental Recap & Technical Buy Zone Confirmation - Newser
Sector ETF performance correlation with KALA BIO Inc.July 2025 WrapUp & Weekly Watchlist of Top Performers - Newser
Signal strength of KALA BIO Inc. stock in tech scannersJuly 2025 Recap & Weekly Market Pulse Alerts - Newser
Using Python tools to backtest KALA BIO Inc. strategiesLong Setup & Real-Time Stock Entry Alerts - Newser
How to build a dashboard for KALA BIO Inc. stock2025 Earnings Surprises & Community Consensus Trade Alerts - Newser
Multi asset correlation models including KALA BIO Inc.Trade Signal Summary & Real-Time Stock Price Movement Reports - Newser
What’s next for KALA BIO Inc. stock priceInsider Selling & Real-Time Price Movement Reports - Newser
KALA CHASEs A Cure For Persistent Non-healing Corneal Defect; Stock Up 95% Within 2 Months - RTTNews
KALA BIO Inc. stock trend forecastIPO Watch & Weekly Watchlist for Hot Stocks - Newser
Can KALA BIO Inc. recover in the next quarterWeekly Earnings Recap & Proven Capital Preservation Tips - Newser
Kala Bio Inc Azioni (KALA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Kala Bio Inc Azioni (KALA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
Jun 24 '25 |
Sale |
4.01 |
3,631 |
14,560 |
62,100 |
| Bazemore Todd | SEE REMARKS |
Jun 24 '25 |
Sale |
4.01 |
4,058 |
16,273 |
83,699 |
| Brazzell Romulus K | SEE REMARKS |
Jun 24 '25 |
Sale |
4.01 |
5,251 |
21,057 |
82,698 |
| Iwicki Mark T | Director |
Jun 24 '25 |
Sale |
4.01 |
13,227 |
53,040 |
258,433 |
1.75%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):